Tissue Regenix Group (LON:TRX) announced its quarterly earnings results on Monday, March 26th. The company reported GBX (1) (($0.01)) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of GBX (1.30) (($0.02)) by GBX 0.30 ($0.00), Bloomberg Earnings reports. Tissue Regenix Group had a negative return on equity of 95.68% and a negative net margin of 346.29%. The business had revenue of GBX 523 million during the quarter.
Tissue Regenix Group stock traded up GBX 0.15 ($0.00) during trading on Wednesday, hitting GBX 10.30 ($0.15). 57,166 shares of the company were exchanged, compared to its average volume of 69,362. Tissue Regenix Group has a 52 week low of GBX 5.62 ($0.08) and a 52 week high of GBX 16.93 ($0.24).
Tissue Regenix Group Company Profile
Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United States and internationally. It operates through Cardiac, Wound Care, Orthopaedics, and GBM-V divisions. The company's decellularisation (dCELL) technology removes DNA and other cellular material from animal and human tissue leaving intact an inert acellular matrix upon which the patient's cells can repopulate.
Receive News & Ratings for Tissue Regenix Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tissue Regenix Group and related companies with MarketBeat.com's FREE daily email newsletter.